Jin Medical International (NASDAQ:ZJYL – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
Earnings & Valuation
This table compares Jin Medical International and Evolus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jin Medical International | $20.69 million | 0.93 | $1.19 million | N/A | N/A |
| Evolus | $297.18 million | 1.55 | -$51.64 million | ($0.67) | -10.42 |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Jin Medical International and Evolus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jin Medical International | 1 | 0 | 0 | 0 | 1.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus target price of $16.00, indicating a potential upside of 129.26%. Given Evolus’ stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Jin Medical International.
Insider & Institutional Ownership
90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Jin Medical International has a beta of 7.23, suggesting that its share price is 623% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
Profitability
This table compares Jin Medical International and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jin Medical International | N/A | N/A | N/A |
| Evolus | -14.39% | N/A | -19.03% |
Summary
Evolus beats Jin Medical International on 7 of the 11 factors compared between the two stocks.
About Jin Medical International
Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Jin Medical International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jin Medical International and related companies with MarketBeat.com's FREE daily email newsletter.
